Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond

share with twitter share with LinkedIn share with facebook
07/28/2020 | 02:23pm EDT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Basel, Switzerland, July 28, 2020

Basilea Pharmaceutica Ltd. ("Basilea" or the "Company") announces today that it completed the repurchase of CHF 47,085,000 in nominal value of outstanding convertible bonds due 2022 (ISIN: CH0305398148; SSN: 30'539'814) ("Existing Bonds") within its partial repurchase offer and the issuance of CHF 97,085,000 new convertible bonds due 2027 (ISIN: CH0554992062; SSN: 55'499'206) ("New Bonds").

By repurchasing CHF 47.085 million of its CHF 200 million Existing Bonds and by issuing CHF 97.085 million New Bonds, the Company managed to make a substantial step in its goal to improve the maturity structure of its debt. Basilea has also earmarked the major part of the net proceeds from the issuance of the New Bonds not used in the repurchase of the Existing Bonds, to further optimize the debt maturity structure.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This announcement regarding the Repurchase Offer does not constitute an offer or an invitation to participate in the Repurchase Offer or the Offering in any jurisdiction in which, or to any person to or from which, it is unlawful to make such invitation or for there to be such participation under applicable securities laws. The distribution of this press release in certain jurisdictions may be restricted by law. Persons into whose possession this press release comes are required to inform themselves about, and to observe, any such restrictions.

No action has been or will be taken in any jurisdiction in relation to the Repurchase Offer that would permit a public offering of securities in any such jurisdiction.

United States

The Repurchase Offer is not being made, and will not be made, directly or indirectly, in or into, or by use of the mail of, or by any means or instrumentality of interstate commerce of or of any facilities of a national securities exchange of, the United States or to or for the account or benefit of, U.S. persons as defined in Regulation S of the Securities Act (each a "U.S. person"). This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone and the internet and other forms of electronic communication. The Bonds may not be tendered for purchase pursuant to the Repurchase Offer by any such use, means, instrumentality or facility from or within the United States or by any persons located or resident in the United States as defined in Regulation S of the U.S. Securities Act of 1933, as amended (the "Securities Act") or to U.S. persons. Accordingly, copies of the Repurchase Offer Notice and any other documents or materials relating to the Repurchase Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to persons located or resident in the United States or to U.S. persons. Any purported offers to tender Bonds pursuant to the Repurchase Offer resulting, directly or indirectly, from a violation of these restrictions will be invalid, and any purported tender of Bonds made by a U.S. person, a person located or resident in the United States or from within the United States or from any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States or any U.S. person will not be accepted.

Each Bondholder participating in the Repurchase Offer will represent to the Offeror, the Joint Dealer Managers and the Tender Agent that it is not located or resident in the United States and is not a U.S. person and is not giving an order to participate in the Repurchase Offer from within the United States or on behalf of a U.S. person.

United Kingdom

The communication of the Repurchase Offer Notice and any other documents or materials relating to the Repurchase Offer is not being made and such documents and/or materials have not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, such documents and/or materials are not being distributed to, are not directed at and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to persons within the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order”)) or falling within Article 43(2) of the Order, or to other persons to whom it may lawfully be communicated (together “relevant persons”). The investment activity to which this document relates will only be engaged in with relevant persons and persons who are not relevant persons should not rely on it.

European Economic Area

In any Member State of the European Economic Area (the "EEA") or in the United Kingdom (each, a "Relevant State"), the Repurchase Offer is only addressed to, and is only directed at, qualified investors in that Relevant State within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). Each person in a Relevant State who receives any communication in respect of the Repurchase Offer contemplated in the Repurchase Offer Notice will be deemed to have represented, warranted and agreed to and with the Joint Dealer Managers, the Tender Agent and the Company that it is a qualified investor within the meaning of the Prospectus Regulation. The Bonds have not been admitted to trading on a regulated market in the European Economic Area or in the United Kingdom.

Switzerland and General

This document and the Repurchase Offer Notice neither constitute a prospectus within the meaning of Articles 652a and 1156 of the Swiss Code of Obligations (as in effect immediately prior to the entry into force of the FinSA) nor a prospectus within the meaning of the listing rules of the SIX Swiss Exchange, a prospectus within the meaning of the FinSA or under any other applicable laws.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone+41 61 606 1102
E-mailmedia_relations@basilea.com 
investor_relations@basilea.com 

This press release can be downloaded from www.basilea.com.

Attachment

Primary Logo

© GlobeNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about BASILEA PHARMACEUTICA AG
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli ..
GL
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26Basilea presents preclinical data on anti-angiogenic activity of derazantinib..
GL
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
AQ
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
AQ
10/13Basilea reports interim results from phase 1/2 study FIDES-02 exploring deraz..
GL
10/12BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA pa..
AQ
More news
Financials
Sales 2020 135 M 148 M 148 M
Net income 2020 -19,2 M -20,9 M -20,9 M
Net Debt 2020 110 M 120 M 120 M
P/E ratio 2020 -25,5x
Yield 2020 -
Capitalization 481 M 525 M 525 M
EV / Sales 2020 4,37x
EV / Sales 2021 3,98x
Nbr of Employees 225
Free-Float 88,3%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 91,38 CHF
Last Close Price 44,52 CHF
Spread / Highest target 214%
Spread / Average Target 105%
Spread / Lowest Target 16,8%
EPS Revisions
Managers
NameTitle
David Veitch Chief Executive Officer
Domenico Scala Chairman
Adesh Kaul Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BASILEA PHARMACEUTICA AG-5.04%528
LONZA GROUP AG57.42%45 407
SEAGEN INC.70.53%33 903
IQVIA HOLDINGS INC.0.78%29 854
CELLTRION, INC.39.78%28 585
MODERNA, INC.236.09%25 940